Bio-Rad Laboratories, Inc. BIO
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- +22.84%
- 1 year
- +22.18%
- Open
- 381.09
- Prev close
- 384.40
- Mkt cap
- 9.96B
- Vol
- 183.09K
- Avg vol
- 255.45K
- EPS
- 7.89
- P/E
- 47.17
- Div yield
- 0.00%
More statistics
- Low
- 368.45
- High
- 381.29
- Forward P/E
- 38.14
- Beta
- 1.07
- Short ratio
- 4.17
- Inst. own
- 91.77%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 374.89
- 200-d avg
- 313.14
- 1y target
- 335.00
3M chart
Events in this range
- Aug 4, 2026Earnings: 2.62; estimate 1.75; surprise 49.71%
- Aug 5, 2026Rating: Wells Fargo · Equal-Weight → Equal-Weight
- Aug 5, 2026Rating: RBC Capital · Outperform → Outperform
- Aug 5, 2026Rating: Citigroup · Neutral → Neutral
- Aug 7, 2026Rating: RBC Capital · Outperform → Outperform
Signals (19)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 2026 | 1 day ago |
| SMA: Bullish | Oct 27, 2026 | 4 days ago |
| SMA: Bullish | Oct 26, 2026 | 5 days ago |
| MACD: Buy Signal | Oct 23, 2026 | 1 week ago |
| SMA: Bearish | Oct 7, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 6, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 5, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 2, 2026 | 4 weeks ago |
| SMA: Bearish | Oct 1, 2026 | 1 month ago |
| SMA: Bearish | Sep 30, 2026 | 1 month ago |
| SMA: Bullish | Sep 29, 2026 | 1 month ago |
| SMA: Bearish | Sep 28, 2026 | 1 month ago |
| SMA: Bullish | Sep 15, 2026 | 1 month ago |
| SMA: Bearish | Sep 14, 2026 | 1 month ago |
| RSI: Overbought | Sep 2, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 1, 2026 | 2 months ago |
| RSI: Overbought | Aug 19, 2026 | 2 months ago |
| RSI: Overbought | Aug 5, 2026 | 2 months ago |
| RSI: Overbought | Aug 3, 2026 | 2 months ago |
Key statistics
- Market cap
- 9.94B
- Enterprise value
- 10.03B
- Trailing P/E
- 47.11
- Forward P/E
- 38.14
- PEG ratio
- 4.01
- Price / sales
- 3.84
- Price / book
- 1.39
- EPS (TTM)
- 7.89
- Beta
- 1.07
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 8.59%
- Revenue (TTM)
- 2.59B
- Revenue growth
- -0.10%
- Free cash flow
- 283.19M
- Total cash
- 1.62B
- Total debt
- 1.37B
- Return on equity
- 3.11%
- Shares outstanding
- 21.68M
- Short % of float
- 6.91%
- 50-day average
- 374.89
- 200-day average
- 313.14
Analyst view
Consensus: hold
- Target (low)
- 280.00
- Target (mean)
- 335.00
- Target (high)
- 390.00
- Strong buy1
- Buy0
- Hold1
- Sell0
- Strong sell1
Next earnings
Nov 4, 2026
Expected Nov 4, 2026. Consensus EPS estimate 2.23.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 30, 2026 | 2.23 | — | — | — |
| Aug 4, 2026 | Jun 30, 2026 | 1.75 | 2.62 | +0.87 | +49.71% |
| Apr 30, 2026 | Mar 31, 2026 | 1.97 | 1.89 | -0.08 | -4.06% |
| Feb 12, 2026 | Dec 31, 2025 | 2.57 | 2.51 | -0.06 | -2.33% |
| Oct 29, 2025 | Sep 30, 2025 | 2.30 | 2.26 | -0.04 | -1.74% |
| Jul 31, 2025 | Jun 30, 2025 | 1.93 | 2.61 | +0.68 | +35.23% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 7, 2026 | RBC Capital | main | Outperform | Outperform |
| Aug 5, 2026 | Citigroup | main | Neutral | Neutral |
| Aug 5, 2026 | RBC Capital | main | Outperform | Outperform |
| Aug 5, 2026 | Wells Fargo | main | Equal-Weight | Equal-Weight |
| May 1, 2026 | Wells Fargo | main | Equal-Weight | Equal-Weight |
| Apr 7, 2026 | Citigroup | down | Buy | Neutral |
About Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- bio-rad.com
News
- Bio-Rad to Participate in Fireside Chat During UBS Global Healthcare Conference
- BIO-key Deploys Identity Security Solution to New Customer Within a Middle East Government's National Security Ecosystem
- Ariel Appreciation Fund Q3 2026 Scorecard: Buys, Sells, And Standouts
- Ariel Fund Q3 2026 Leaders And Laggards
Your note
Sign in to keep a note on BIO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALLISON SCHWARTZ | Director | Conversion of Exercise of derivative security | Sep 3, 2026 | 1,734 |
| BARRY JAMES | Officer | Conversion of Exercise of derivative security | Sep 3, 2026 | 2,024 |
| COREY COLLEEN | Officer | Conversion of Exercise of derivative security | Sep 4, 2025 | 19,550 |
| CROWLEY MICHAEL W | Officer | Conversion of Exercise of derivative security | Mar 13, 2025 | 8,171 |
| DIVINCENZO JONATHAN P | President | Conversion of Exercise of derivative security | Oct 22, 2026 | 2,881 |
| ENGELHARDT EVA ANETTE | Officer | Conversion of Exercise of derivative security | Sep 3, 2026 | 1,828 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| First Eagle Investment Management, LLC | 12.02% | 2,606,219 | 968.77M | Jun 29, 2026 |
| Blackrock Inc. | 7.84% | 1,698,929 | 631.52M | Jun 29, 2026 |
| Dimensional Fund Advisors LP | 4.36% | 944,548 | 351.10M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 3.81% | 826,972 | 307.40M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 3.77% | 816,198 | 303.39M | Jun 29, 2026 |
| Ariel Investments, LLC | 3.77% | 816,751 | 303.60M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| First Eagle Funds-First Eagle Global Fund | 8.67% | 1,878,739 | 698.36M | Jul 30, 2026 |
| SmallCap World Fund Inc | 4.29% | 930,906 | 346.03M | Sep 29, 2026 |
| iShares Trust-iShares Core S&P Mid-Cap ETF | 2.99% | 648,604 | 241.10M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.70% | 584,782 | 217.37M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 1.95% | 423,193 | 157.31M | Jun 29, 2026 |
| Ariel Investment Trust-Ariel Fund | 1.61% | 349,270 | 129.83M | Jun 29, 2026 |